BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 10362331)

  • 1. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
    Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
    Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
    Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
    Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A
    Br J Cancer; 1995 Mar; 71(3):583-6. PubMed ID: 7880742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
    Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
    J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study.
    Gallardo-Rincón D; Oñate-Ocaña LF; Calderillo-Ruiz G
    Ann Surg Oncol; 2000; 7(1):45-50. PubMed ID: 10674448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
    Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
    Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
    Atiq OT; Kelsen DP; Shiu MH; Saltz L; Tong W; Niedzwiecki D; Trochanowski B; Lin S; Toomasi F; Brennan M
    J Clin Oncol; 1993 Mar; 11(3):425-33. PubMed ID: 8445416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    Fuchs CS; Niedzwiecki D; Mamon HJ; Tepper JE; Ye X; Swanson RS; Enzinger PC; Haller DG; Dragovich T; Alberts SR; Bjarnason GA; Willett CG; Gunderson LL; Goldberg RM; Venook AP; Ilson D; O'Reilly E; Ciombor K; Berg DJ; Meyerhardt J; Mayer RJ
    J Clin Oncol; 2017 Nov; 35(32):3671-3677. PubMed ID: 28976791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
    Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
    N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
    Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
    Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
    J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
    Leichman L; Silberman H; Leichman CG; Spears CP; Ray M; Muggia FM; Kiyabu M; Radin R; Laine L; Stain S
    J Clin Oncol; 1992 Dec; 10(12):1933-42. PubMed ID: 1453207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
    Büyükçelik A; Onur H; Akbulut H; Bülent Y; Ensari A; Utkan G; Onal BS; Içli F
    Tumori; 2005; 91(4):302-8. PubMed ID: 16277093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
    Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.